Literature DB >> 28726181

KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?

Federica Grillo1,2, Luca Valle3, Diego Ferone4,5, Manuela Albertelli4,5, Maria Pia Brisigotti3, Giuseppe Cittadini6, Alessandro Vanoli7, Roberto Fiocca3,4, Luca Mastracci3,4.   

Abstract

PURPOSE: Ki-67 heterogeneity can impact on gastroenteropancreatic neuroendocrine tumor grade assignment, especially when tissue is scarce. This work is aimed at devising adequacy criteria for grade assessment in biopsy specimens.
METHOD: To analyze the impact of biopsy size on reliability, 360 virtual biopsies of different thickness and lengths were constructed. Furthermore, to estimate the mean amount of non-neoplastic tissue component present in biopsies, 28 real biopsies were collected, the non-neoplastic components (fibrosis and inflammation) quantified and the effective area of neoplastic tissue calculated for each biopsy.
RESULTS: Heterogeneity of Ki-67 distribution, G2 tumors and biopsy size all play an important role in reducing the reliability of biopsy samples in Ki-67-based grade assignment. In particular in G2 cases, 59.9% of virtual biopsies downgraded the tumor and the smaller the biopsy, the more frequent downgrading occurs. In real biopsies the presence of non-neoplastic tissue reduced the available total area by a mean of 20%.
CONCLUSIONS: By coupling the results from these two different approaches we show that both biopsy size and non-neoplastic component must be taken into account for biopsy adequacy. In particular, we can speculate that if the minimum biopsy area, necessary to confidently (80% concordance) grade gastro-entero-pancreatic neuroendocrine tumors on virtual biopsies ranges between 15 and 30 mm2, and if real biopsies are on average composed of only 80% of neoplastic tissue, then biopsies with a surface area not <12 mm2 should be performed; using 18G needles, this corresponds to a minimum total length of 15 mm.

Entities:  

Keywords:  Biopsy; Gastroenteropancreatic neuroendocrine tumors; Grade; Ki-67

Mesh:

Substances:

Year:  2017        PMID: 28726181     DOI: 10.1007/s12020-017-1364-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  21 in total

1.  Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact.

Authors:  Deniz L Aslan; H Evin Gulbahce; Stefan E Pambuccian; J Carlos Manivel; Jose Jessurun
Journal:  Am J Clin Pathol       Date:  2005-06       Impact factor: 2.493

2.  Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index.

Authors:  B Weynand; I Borbath; V Bernard; C Sempoux; J-F Gigot; C Hubert; V Lannoy; P H Deprez; A Jouret-Mourin
Journal:  Cytopathology       Date:  2013-11-15       Impact factor: 2.073

3.  Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  K Öberg; U Knigge; D Kwekkeboom; A Perren
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

4.  Section detachment in immunohistochemistry: causes, troubleshooting, and problem-solving.

Authors:  Alessandro Gambella; Lucia Porro; Simona Pigozzi; Roberto Fiocca; Federica Grillo; Luca Mastracci
Journal:  Histochem Cell Biol       Date:  2017-03-11       Impact factor: 4.304

5.  Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.

Authors:  Laura H Tang; Mithat Gonen; Cyrus Hedvat; Irvin M Modlin; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

6.  Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study.

Authors:  Alberto Larghi; Gabriele Capurso; Antonella Carnuccio; Riccardo Ricci; Sergio Alfieri; Domenico Galasso; Francesca Lugli; Antonio Bianchi; Francesco Panzuto; Laura De Marinis; Massimo Falconi; Gianfranco Delle Fave; Giovanni Battista Doglietto; Guido Costamagna; Guido Rindi
Journal:  Gastrointest Endosc       Date:  2012-09       Impact factor: 9.427

7.  Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics?

Authors:  Vinciane Rebours; Jacqueline Cordova; Anne Couvelard; Monique Fabre; Laurent Palazzo; Marie Pierre Vullierme; Olivia Hentic; Alain Sauvanet; Alain Aubert; Pierre Bedossa; Philippe Ruszniewski
Journal:  Dig Liver Dis       Date:  2015-06-20       Impact factor: 4.088

8.  Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors.

Authors:  Toshiyuki Hasegawa; Kenji Yamao; Susumu Hijioka; Vikram Bhatia; Nobumasa Mizuno; Kazuo Hara; Hiroshi Imaoka; Yasumasa Niwa; Masahiro Tajika; Shinya Kondo; Tutomu Tanaka; Yasuhiro Shimizu; Taira Kinoshita; Takuhiro Kohsaki; Isao Nishimori; Shinji Iwasaki; Toshiji Saibara; Waki Hosoda; Yasushi Yatabe
Journal:  Endoscopy       Date:  2013-11-11       Impact factor: 10.093

9.  Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor.

Authors:  Federica Grillo; Manuela Albertelli; Maria Pia Brisigotti; Tiziana Borra; Mara Boschetti; Roberto Fiocca; Diego Ferone; Luca Mastracci
Journal:  Neuroendocrinology       Date:  2015-08-25       Impact factor: 4.914

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  11 in total

1.  In focus in HCB.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2021-08-20       Impact factor: 4.304

2.  Amyloid-Rich Pancreatic Neuroendocrine Tumors: a Potential Diagnostic Pitfall in Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytology (EUS-FNAC).

Authors:  Alessandro Gambella; Enrico Costantino Falco; Jasna Metovic; Francesca Maletta; Claudio De Angelis; Roberta Maragliano; Silvia Uccella; Donatella Pacchioni; Mauro Papotti
Journal:  Endocr Pathol       Date:  2021-06       Impact factor: 3.943

3.  Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.

Authors:  Josephine Graf; Ulrich-Frank Pape; Henning Jann; Timm Denecke; Ruza Arsenic; Winfried Brenner; Marianne Pavel; Vikas Prasad
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-14       Impact factor: 9.236

4.  Pathology Reporting in Neuroendocrine Neoplasms of the Digestive System: Everything You Always Wanted to Know but Were Too Afraid to Ask.

Authors:  Manuela Albertelli; Federica Grillo; Fabio Lo Calzo; Giulia Puliani; Carmen Rainone; Annamaria Anita Livia Colao; Antongiulio Faggiano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-23       Impact factor: 5.555

5.  Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease.

Authors:  Espen Thiis-Evensen; Amalie Christine Poole; Hong-Thien Thi Nguyen; Jon Sponheim
Journal:  BMC Cancer       Date:  2020-05-24       Impact factor: 4.430

6.  A Preoperative Clinical Risk Score Including C-Reactive Protein Predicts Histological Tumor Characteristics and Patient Survival after Surgery for Sporadic Non-Functional Pancreatic Neuroendocrine Neoplasms: An International Multicenter Cohort Study.

Authors:  Florian Primavesi; Valentina Andreasi; Frederik J H Hoogwater; Stefano Partelli; Dominik Wiese; Charlotte Heidsma; Benno Cardini; Eckhard Klieser; Katharina Marsoner; Uwe Fröschl; Sabine Thalhammer; Ines Fischer; Georg Göbel; Andreas Hauer; Tobias Kiesslich; Philipp Ellmerer; Reinhold Klug; Daniel Neureiter; Helwig Wundsam; Franz Sellner; Peter Kornprat; Reinhold Függer; Dietmar Öfner; Elisabeth J M Nieveen van Dijkum; Detlef K Bartsch; Ruben H J de Kleine; Massimo Falconi; Stefan Stättner
Journal:  Cancers (Basel)       Date:  2020-05-14       Impact factor: 6.639

7.  Endoscopic ultrasound-guided side-fenestrated needle biopsy sampling is sensitive for pancreatic neuroendocrine tumors but inadequate for tumor grading: a prospective study.

Authors:  Alexander Appelstrand; Fredrik Bergstedt; Anna-Karin Elf; Henrik Fagman; Per Hedenström
Journal:  Sci Rep       Date:  2022-04-08       Impact factor: 4.379

8.  Efficiency of an endoscopic resection strategy for management of submucosal tumors < 20 mm in the upper gastrointestinal tract.

Authors:  Fabrice Caillol; Elise Meunier; Christophe Zemmour; Jean Phillipe Ratone; Jerome Guiramand; Solene Hoibian; Yanis Dahel; Flora Poizat; Marc Giovannini
Journal:  Endosc Int Open       Date:  2022-04-14

9.  Methods for restoration of ki67 antigenicity in aged paraffin tissue blocks.

Authors:  Federica Grillo; Michela Campora; Simona Pigozzi; Silvia Bonadio; Luca Valle; Jacopo Ferro; Michele Paudice; Beatrice Dose; Luca Mastracci
Journal:  Histochem Cell Biol       Date:  2021-04-10       Impact factor: 4.304

Review 10.  Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors-Need for a Conductor.

Authors:  Alexander R Siebenhüner; Melanie Langheinrich; Juliane Friemel; Niklaus Schäfer; Dilmurodjon Eshmuminov; Kuno Lehmann
Journal:  Cancers (Basel)       Date:  2022-03-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.